ebook: How to start your own lab
Learn practical tips from eight Principal Investigators about how to start your own lab.
List view / Grid view
Learn practical tips from eight Principal Investigators about how to start your own lab.
Collaborative research has revealed two hallmarks of COVID-19 infection associated with more severe symptoms that can be identified by a blood test.
Researchers demonstrate that a subpopulation of circulating white blood cells can act as an early indicator of vaccine efficacy, with potential implications for COVID-19 drug development.
Macaques were protected against SARS-CoV-2 infection both after an initial infection and vaccination with a prototype vaccine, researchers suggest humans could respond similarly.
A detailed analysis of the body's immune response to COVID-19 has revealed that it can recognise SARS-CoV-2 in many ways, meaning vaccines can be used to stop the spread of the virus.
Researchers have found that antibodies produced in response to SARS and COVID-19 are cross-reactive, but not cross protective in cells and mice.
A new article has outlined the body's inflammatory response to COVID-19 infection, saying that lipid mediators derived from omega-3 fatty acids could prevent life-threatening inflammation.
Researchers have shown that adding the RPL6 protein to malaria vaccines was successful at protecting mice against the condition.
A vaccine currently in Phase I clinical trials was effective at inducing immune responses against SARS-CoV-2 in mice and rhesus macaques.
Two antibodies named B38 and H4 could work as a COVID-19 therapeutic by neutralising the virus, say researchers in China.
Dr Bernard Fox from Providence Cancer Institute explains how OncoSec’s CORVax12 vaccine works to potentially combat COVID-19.
A new kind of dendritic cell has been discovered by researchers and could play a role presenting antigens to other immune cells during respiratory virus infections.
A MERS vaccine, which uses RNA-based adjuvants, has demonstrated efficacy in non-human primates and is now being developed as a prophylactic for COVID-19.
An antibody that neutralises both SARS-CoV and SARS-CoV-2 in cell cultures has been discovered by researchers and could be used to treat COVID-19.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.